ASCIMINIB

Information current as at: 1 July 2026

PBAC meeting date: March 2026
Legend: Completed N In progress Not applicable N Yet to commence

Submission Details

Brand name:
  • Scemblix®
Form and strength:

Please search for and view the meeting agenda from the relevant meeting for more information

Submission sponsor:
NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LIMITED
Condition/indication:
(therapeutic use)
  • Chronic myeloid leukaemia (CML)
Listing requested:
Please see meeting agenda for more information
Funding program:
PBS General Schedule
Request authority level:
Please see meeting agenda for more information
PBAC Submission type:
Change to listing (Category 4)
Comment:
--
Other PBAC consideration:
--

Progress Details

Submission received for:
March 2026 PBAC meeting
Opportunity for consumer comment:
Open 19/11/2025 and close 21/01/2026 (see PBS Website)
PBAC meeting:
Held on 11/03/2026
PBAC outcome published:
Not Applicable (see PBAC Outcomes)
Lodgement of required documentation:
Not applicable
Agreement to listing arrangements:
Not applicable
Government processes:
Not applicable
Medicine listed on the PBS:
Not applicable
Glossary

PBAC Outcome

PBAC Recommendation:
Please see the Outcomes from the relevant meeting for more information
Case ID
a1150
Page last updated
30 June 2026
Return to the Medicine Status Listing
v.9.19